MedTrace Logo

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT01837251 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 682

Last updated 2021-07-13

No results posted yet for this study

Summary

Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.

Conditions

  • Recurrent Platinum-sensitive Ovarian Cancer

Interventions

DRUG

Carboplatin

DRUG

PLD

BIOLOGICAL

Bevacizumab

Sponsors & Collaborators

  • Arbeitsgemeinschaft Gynaekologische Onkologie Austria

    collaborator OTHER

  • ARCAGY/ GINECO GROUP

    collaborator OTHER

  • Australia New Zealand Gynaecological Oncology Group

    collaborator OTHER

  • Scottish Gynaecological Cancer Study Group

    collaborator OTHER

  • AGO Research GmbH

    lead INDUSTRY

Principal Investigators

  • Jacobus Pfisterer, PhD MD · AGO Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Australia
  • Austria
  • Belgium
  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01837251 on ClinicalTrials.gov